SIREN : 784611857
SELF BLANC DRUG is a French company founded 58 years ago, specialized in the sector Blanchisserie-teinturerie de détail. Based in PARIS (75015), this company of category PME shows in 2023 a revenue of 4.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4 043 276 € | 3 446 907 € | 2 827 808 € | 2 552 934 € | 3 140 267 € | 2 791 357 € | 2 626 558 € | 2 670 794 € |
| Net income | 185 796 € | 96 281 € | -14 856 € | -34 846 € | 45 964 € | 26 794 € | 42 444 € | 65 837 € |
| EBITDA | 257 348 € | 234 872 € | -6 393 € | -65 928 € | 200 346 € | -106 282 € | 82 925 € | -69 939 € |
| Net margin | 4.6% | 2.8% | -0.5% | -1.4% | 1.5% | 1.0% | 1.6% | 2.5% |
In 2023, SELF BLANC DRUG achieves revenue of 4.0 M€. Over the period 2016-2023, the company shows strong growth with a CAGR (compound annual growth rate) of +6.1%. Vs 2022, growth of +17% (3.4 M€ -> 4.0 M€). After deducting consumption (787 k€), gross margin stands at 3.3 M€, i.e. a rate of 81%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 257 k€, representing 6.4% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 186 k€, i.e. 4.6% of revenue. This profit can be retained or distributed to shareholders.
4 043 276 €
3 256 188 €
257 348 €
186 399 €
185 796 €
6.4%
The debt ratio (= Financial debt / Equity x 100) stands at 55%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.1 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 5.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
55.446%
43.262%
5.167%
4.061
20.2%
In 2023, the debt ratio of SELF BLANC DRUG (55.45) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2023, the financial autonomy of SELF BLANC DRUG (43.3%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2023, the repayment capacity of SELF BLANC DRUG (4.06) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 106.40. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 5.3x. Operating income very largely covers interest expenses: high safety margin.
106.4
5.339
In 2023, the liquidity ratio of SELF BLANC DRUG (106.40) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2023, the interest coverage of SELF BLANC DRUG (5.3x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 15 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 91 days. Excellent situation: suppliers finance 76 days of the operating cycle (retail model). Inventory turnover is 17 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 29 days of revenue, i.e. 326 k€ to permanently finance. Over 2016-2023, WCR increased by +81%, requiring additional financing.
326 090 €
15 j
91 j
17 j
29 j
Indicative estimate only : the number of comparable transactions in this sector is limited (23 transactions). This range of 1 205 145€ to 3 215 545€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 23 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SELF BLANC DRUG with other companies in the same sector:
Voir toutes les statistiques du secteur Blanchisserie-teinturerie de détail
The revenue of SELF BLANC DRUG in 2023 is 4.0 M€.
Yes, SELF BLANC DRUG generated a net profit of 186 k€ in 2023.
The headquarters of SELF BLANC DRUG is located in PARIS (75015), in the department Paris.
The tax return of SELF BLANC DRUG is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SELF BLANC DRUG operates in the sector Blanchisserie-teinturerie de détail (NAF code 96.01B). See the 'Sector positioning' section above to compare the company with its competitors.